The first study to visually document the efficacy of ‘Neoral’, Novartis' microemulsion formulation of cyclosporin, in severe, recalcitrant plaque psoriasis has shown that the drug effectively relieves signs and symptoms of this disease such as pain, itching, scaling and irritation. Several studies have shown that cyclosporin is useful in this condition, as evidenced by improvements in Psoriasis Area and Severity Index (PASI) scores, but until now none of the studies had actually visually documented improvements in skin. Results from the study were released at the 57th Annual Meeting of the American Academy of Dermatology [New Orleans, US; March 1999].